|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Boehringer Ingelheim Pharmaceuticals |
|---|---|
| Information provided by: | Boehringer Ingelheim Pharmaceuticals |
| ClinicalTrials.gov Identifier: | NCT00274066 |
Purpose
To evaluate acute effect of single dose of ipratropium (Atrovent) or fenoterol (Berotec) in comparison to placebo when given to COPD patients on pharmacodynamic steady state of tiotropium (Spiriva)
| Condition | Intervention | Phase |
|---|---|---|
|
Pulmonary Disease, Chronic Obstructive |
Drug: Tiotropium + placebo Drug: Tiotropium + ipratropium Drug: Tiotropium + fenoterol |
Phase III |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Efficacy Study |
| Official Title: | The Acute Bronchodilator Effects of a Single Dose (2 Puffs) of the Short-acting Anticholinergic Ipratropium Bromide (40 Mcg) and the Short-acting Beta-adrenergic Fenoterol (200 Mcg) in Comparison to Placebo on Top of Pharmacodynamic Steady State of Once-daily Tiotropium (18 Mcg) Inhalation Capsule in |
| Estimated Enrollment: | 64 |
| Study Start Date: | October 2002 |
| Estimated Study Completion Date: | September 2003 |
In case mono-bronchodilator therapy does not control symptoms of COPD adequately or if regular maintenance therapy is desired, a therapeutic intervention with a combination of bronchodilators is recommended. The risks of side-effects increases with increasing dose of any drug and, therefore, the most important rationale for combination therapy is a very favourable ratio of efficacy and safety. Knowing that anticholinergic and beta-adrenergic agents achieve their bronchodilating effects by different mechanisms, in particular the combination of these agents has proven to be beneficial in the management of COPD. Based on the established clinical benefits, tiotropium is an attractive and promising agent for the first-line long-term maintenance therapy in COPD. This also implies that a therapeutic intervention with other bronchodilators will be prescribed in daily practice. At present no studies on combination therapy with short-acting agents are available. Therefore, using a double-blind, randomised, crossover design, the bronchodilator effects of single doses of ipratropium or fenoterol were compared with placebo when added on top of steady state tiotropium. Patients were pre-treated with tiotropium to achieve this pharmacodynamic steady state. Serial lung function tests (FEV1, FVC, Raw, sGaw) were conducted following add-on of the short-acting bronchodilators or placebo.
Study Hypothesis:
H0: there is no difference between treatments in mean peak FEV1 H1: there is a difference between treatments in mean peak FEV1
Comparison(s):
Add-on of placebo was compared to add-on of ipratropium or add-on of fenoterol. The comparison of ipratropium with placebo was primary. The other 2 pair-wise comparisons were secondary.
Eligibility| Ages Eligible for Study: | 40 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion:
Exclusion:
Contacts and Locations| Netherlands | |
| Boehringer Ingelheim Investigational Site | |
| Groningen, Netherlands, 9700 RB | |
| Amphia Ziekenhuis | |
| Breda, Netherlands, 4819 EV | |
| Afdeling longziekten | |
| Winschoten, Netherlands, 9670 RA | |
| Gelre Ziekenhuizen | |
| Zutphen, Netherlands, 7207 BA | |
| Twenteborg Ziekenhuis | |
| Almelo, Netherlands, 7609 PP | |
| Study Chair: | Boehringer Ingelheim Study Coordinator | Boehringer Ingelheim BV/Alkmaar |
More Information
| Study ID Numbers: | 205.258 |
| Study First Received: | January 9, 2006 |
| Last Updated: | September 24, 2009 |
| ClinicalTrials.gov Identifier: | NCT00274066 History of Changes |
| Health Authority: | Netherlands: IGZ Health Inspection |
|
Parasympatholytics Respiratory System Agents Disease Attributes Neurotransmitter Agents Cholinergic Antagonists Molecular Mechanisms of Pharmacological Action Adrenergic Agents Physiological Effects of Drugs Reproductive Control Agents Cholinergic Agents Adrenergic Agonists Lung Diseases, Obstructive Pathologic Processes Respiratory Tract Diseases Tocolytic Agents |
Therapeutic Uses Tiotropium Adrenergic beta-Agonists Sympathomimetics Fenoterol Anti-Asthmatic Agents Pharmacologic Actions Ipratropium Autonomic Agents Lung Diseases Chronic Disease Peripheral Nervous System Agents Bronchodilator Agents Pulmonary Disease, Chronic Obstructive |